All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.

The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Join our

Treating classical Hodgkin lymphoma: Spotlight on targeted therapies

with Gilles Salles, Paul Bröckelmann, and Ann S. LaCasce

Saturday, November 2, 2024
8:50-9:50 CET

Register now

This independent educational activity is sponsored by Takeda. All content is developed independently by the faculty. Funders are allowed no direct influence on the content of this activity.

  TRANSLATE

The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.

The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene and Roche, and supported through educational grants from Bristol Myers Squibb, Ipsen Biopharmaceuticals, Pfizer, and Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC. View funders.

2023-10-16T10:03:10.000Z

How can we improve care for elderly patients with HL?

Oct 16, 2023
Share:
Learning objective: After reading this article, learners will be able to cite a new clinical development in HL.

During the Society of Hematologic Oncology (SOHO) 2023 Congress, the Lymphoma Hub spoke to Jonathan Friedberg, James P. Wilmot Cancer Centre, New York, US. We asked, How can we improve care for elderly patients with HL?

How can we improve care for elderly patients with HL?

Firstly, Friedberg explains that older patients (aged 60 years) with Hodgkin lymphoma have lower survival outcomes and are often under-represented in clinical trials, such as ECHELON-1 (NCT01712490; <10% of the population aged 60 years). He concludes that specific randomized trials incorporating fitness assessments could improve outcomes for this patient population, with checkpoint inhibitors shown to be a promising treatment option to manage autoimmune adverse events.

Understanding your specialty helps us to deliver the most relevant and engaging content.

Please spare a moment to share yours.

Please select or type your specialty

  Thank you

Your opinion matters

HCPs, what is your preferred format for educational content on the Lymphoma Hub?
20 votes - 11 days left ...

Newsletter

Subscribe to get the best content related to lymphoma & CLL delivered to your inbox